Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Shares Outstanding (Diluted Average): 2009-2023

Historic Shares Outstanding (Diluted Average) for Gyre Therapeutics (GYRE) over the last 6 years, with Sep 2023 value amounting to $38.0 million.

  • Gyre Therapeutics' Shares Outstanding (Diluted Average) rose 20.16% to $38.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was $38.0 million, marking a year-over-year increase of 20.16%. This contributed to the annual value of $31.5 million for FY2022, which is 2.95% up from last year.
  • According to the latest figures from Q3 2023, Gyre Therapeutics' Shares Outstanding (Diluted Average) is $38.0 million, which was up 0.47% from $37.8 million recorded in Q2 2023.
  • Gyre Therapeutics' Shares Outstanding (Diluted Average)'s 5-year high stood at $38.0 million during Q1 2023, with a 5-year trough of $30.6 million in Q4 2021.
  • For the 3-year period, Gyre Therapeutics' Shares Outstanding (Diluted Average) averaged around $33.3 million, with its median value being $31.5 million (2022).
  • Data for Gyre Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY grew of 20.75% (in 2023) over the last 5 years.
  • Gyre Therapeutics' Shares Outstanding (Diluted Average) (Quarterly) stood at $30.6 million in 2021, then grew by 2.95% to $31.5 million in 2022, then rose by 20.16% to $38.0 million in 2023.
  • Its Shares Outstanding (Diluted Average) stands at $38.0 million for Q3 2023, versus $37.8 million for Q2 2023 and $38.0 million for Q1 2023.